← All trials
NCT05804032
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 14, 2023
- Primary completion
- Jul 24, 2025
- Completion date
- Jul 24, 2026
- First posted
- Apr 7, 2023
- Last posted
- Nov 8, 2023
- Enrollment
- 514
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of HeidelbergLead sponsor
- Deutsche Studiengruppe Multiples MyelomCollaborator
- Koordinierungszentren für Klinische Studien bzw. Zentren für klinische StudienCollaborator
- SanofiCollaborator
- University of HeidelbergReponsible party - principal investigator
- University of HeidelbergSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.